Cargando…

Dissociable effects of dopaminergic medications on depression symptom dimensions in Parkinson’s disease

BACKGROUND: Depression in Parkinson’s disease (PD) is common, disabling and responds poorly to standard antidepressant medication. Motivational symptoms of depression, such as apathy and anhedonia, are particularly prevalent in depression in PD and predict poor response to antidepressant treatment....

Descripción completa

Detalles Bibliográficos
Autores principales:	Costello, Harry, Schrag, Anette-Eleonore, Howard, Robert, Roiser, Jonathan P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327242/ https://www.ncbi.nlm.nih.gov/pubmed/37425947 http://dx.doi.org/10.1101/2023.06.30.23292073

Ejemplares similares

Longitudinal decline in striatal dopamine transporter binding in Parkinson’s disease: associations with apathy and anhedonia
por: Costello, Harry, et al.
Publicado: (2023)

Late onset depression: dopaminergic deficit and clinical features of prodromal Parkinson’s disease: a cross-sectional study
por: Kazmi, Hiba, et al.
Publicado: (2021)

Influence of Depressive Symptoms on Dopaminergic Treatment of Parkinson’s Disease
por: Hanganu, Alexandru, et al.
Publicado: (2014)

The prediagnostic phase of Parkinson's disease
por: Noyce, Alastair John, et al.
Publicado: (2016)

Antidepressant medications in dementia: evidence and potential mechanisms of treatment-resistance
por: Costello, Harry, et al.
Publicado: (2023)

The Role of Cognitive-Behavioural Therapy for Patients with Depression in Parkinson's Disease
por: Charidimou, Andreas, et al.
Publicado: (2011)

Implications of dopaminergic medication withdrawal in Parkinson’s disease
por: Koschel, J., et al.
Publicado: (2021)

Disrupted reward processing in Parkinson’s disease and its relationship with dopamine state and neuropsychiatric syndromes: a systematic review and meta-analysis
por: Costello, Harry, et al.
Publicado: (2022)

The prodromes of Parkinson's disease
por: Rees, Richard Nathaniel, et al.
Publicado: (2018)

Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson’s disease: evidence for dopaminergic basis?
por: Qamar, MA, et al.
Publicado: (2017)

Brain iron deposition is linked with cognitive severity in Parkinson’s disease
por: Thomas, George Edward Calver, et al.
Publicado: (2020)

Dissociation of Progressive Dopaminergic Neuronal Death and Behavioral Impairments by Bax Deletion in a Mouse Model of Parkinson's Diseases
por: Kim, Tae Woo, et al.
Publicado: (2011)

Psychiatric Symptom Dimensions Are Associated With Dissociable Shifts in Metacognition but Not Task Performance
por: Rouault, Marion, et al.
Publicado: (2018)

Parkinson's disease and dopaminergic neurons
Publicado: (2012)

Motivational modulation of bradykinesia in Parkinson’s disease off and on dopaminergic medication
por: Kojovic, Maja, et al.
Publicado: (2014)

Effect of Dopaminergic Medication on Postural Sway in Advanced Parkinson’s Disease
por: Revilla, Fredy J., et al.
Publicado: (2013)

Beta burst dynamics in Parkinson’s disease OFF and ON dopaminergic medication
por: Tinkhauser, Gerd, et al.
Publicado: (2017)

Dopaminergic Medication Increases Reliance on Current Information in Parkinson’s Disease
por: Vilares, Iris, et al.
Publicado: (2017)

Theory of mind deficits in Parkinson’s disease are not modulated by dopaminergic medication
por: Usnich, Tatiana, et al.
Publicado: (2023)

The Validity of Health-Related Quality of Life Instruments in Patients With Late-Stage Parkinson’s Disease
por: Ramadhan, Mouhammed, et al.
Publicado: (2022)

Caregiver Burden and Quality of Life in Late Stage Parkinson’s Disease
por: Rosqvist, Kristina, et al.
Publicado: (2022)

Author Correction: Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson’s disease: evidence for dopaminergic basis?
por: Qamar, M. A., et al.
Publicado: (2023)

Clinical implications for dopaminergic and functional neuroimage research in cognitive symptoms of Parkinson’s disease
por: Hirano, Shigeki
Publicado: (2021)

Mild Cognitive Impairment in Parkinson’s Disease—What Is It?
por: Weil, Rimona S., et al.
Publicado: (2018)

The experience of Anxiety for people with Parkinson’s disease
por: Blundell, Emma. K., et al.
Publicado: (2023)

Dopaminergic Modulation of Medial Prefrontal Cortex Deactivation in Parkinson Depression
por: Andersen, Anders H., et al.
Publicado: (2015)

Influence of Dopaminergic Medication on Conditioned Pain Modulation in Parkinson's Disease Patients
por: Grashorn, Wiebke, et al.
Publicado: (2015)

The Effect of Dopaminergic Medication on Beat-Based Auditory Timing in Parkinson’s Disease
por: Cameron, Daniel J., et al.
Publicado: (2016)

Dopaminergic medication reduces striatal sensitivity to negative outcomes in Parkinson’s disease
por: McCoy, Brónagh, et al.
Publicado: (2019)

Depressive symptoms in Parkinson’s disease and in non-neurological medical illnesses
por: Assogna, Francesca, et al.
Publicado: (2013)

Parkinson’s Disease, the Dopaminergic Neuron and Gammahydroxybutyrate
por: Mamelak, Mortimer
Publicado: (2018)

Diverse midbrain dopaminergic neuron subtypes and implications for complex clinical symptoms of Parkinson’s disease
por: Carmichael, Kathleen, et al.
Publicado: (2021)

Beyond the Dopaminergic System: Lessons Learned from levodopa Resistant Symptoms in Parkinson's Disease
por: Antonini, Angelo, et al.
Publicado: (2023)

Distinct Role of Striatal Functional Connectivity and Dopaminergic Loss in Parkinson’s Symptoms
por: Dukart, Juergen, et al.
Publicado: (2017)

Arm swing responsiveness to dopaminergic medication in Parkinson’s disease depends on task complexity
por: Warmerdam, Elke, et al.
Publicado: (2021)

Short-term effect of dopaminergic medication on speech in early-stage Parkinson’s disease
por: Tykalova, Tereza, et al.
Publicado: (2022)

Change in the incidence of Parkinson’s disease in a large UK primary care database
por: Okunoye, Olaitan, et al.
Publicado: (2022)

Current concepts and controversies in the pathogenesis of Parkinson’s disease dementia and Dementia with Lewy Bodies
por: Weil, Rimona S., et al.
Publicado: (2017)

Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson’s disease
por: Schrag, A, et al.
Publicado: (2022)

Perspectives on Care for Late-Stage Parkinson's Disease
por: Rosqvist, Kristina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jd2uvl7qkkk0gh9hsadkj1p9be